Xarelto: new Anticoagulant under fire

Concerns regarding the safety of the new anticoagulant Xarelto have not been dispelled. Trials carried out with the drug have resulted in a number of fatalities. Dubious practices are also being used to market the product. There are justified fears that a high-risk, over-expensive product with no additional therapeutic benefit is being forced onto the market.

=> British Medical Journal investigation casts doubt over Xarelto trial

=> Countermotion to Bayer Shareholder Meeting: Xarelto under Fire

=> Xarelto: BAYER pays compensation in China

=> Public Citizen: Use of Anti-Clotting Drug Should Not Be Expanded to Prevent Strokes

=> Journalist Ruhi Kandhari from Delhi speaking in BAYER ASM on rivaroxaban trials in India

=> Xarelto: Trial-related deaths in India

=> Safety Concerns with Blood Thinner Xarelto

=> FDA staff fears over bleeding risk of Bayer/J&J’s rivaroxaban

=> NICE asks for more info on Bayer's Xarelto